Stock code: 300759.SZ

Stock code: 3759.HK

2024

Annual Results

M a r c h 2 0 2 5Disclaimer

The documents opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co. Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in

presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to

the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law and the

recipients into whose possession this Document comes should inform themselves about and observe such restrictions. By accessing this Document you are agreeing (i) that you have read and agree to comply with the

contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell or any solicitation of any offer to subscribe for or

purchase any securities in any jurisdiction in which the making of such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise

be in compliance with the laws and regulations of such jurisdiction and nothing contained herein shall form the basis of any investment decision contract or commitment whatsoever. This Document contains no

information or material which may result in it being deemed (1) to be an advertisement invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and

Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being

able to invoke any exemption available under the laws of Hong Kong and is subject to material change without notice.The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933 as amended (the “U.S. Securities Act”) or under the laws of any state of the United States. This Document

does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed directly or indirectly in or into the United

States (including its territories and possessions any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an

exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any

copy hereof may be directly or indirectly taken or transmitted into or distributed in the United States Canada Australia Japan PRC Hong Kong or any other jurisdiction which prohibits the same except in compliance

with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request the recipient will promptly return this Document and any

other written information made available in the presentation without retaining any copies.This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation warranty or undertaking express or implied is given

and so far as is permitted by law no responsibility or liability is accepted by any person (for the avoidance of doubt including but not limited to the Company and its affiliates controlling persons directors officers

partners employees agents representatives or advisers of any of the foregoing) with respect to the accuracy reliability correctness fairness or completeness of this Document or its contents. The information

communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will" "expects" “intends” “plans to” and "anticipates" and words of

similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the

Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ materially from these forward-looking statements. In particular but without limitation no representation

or warranty is given as to the achievement or reasonableness of and no reliance should be placed on any assumptions projections targets estimates forecasts or any forward-looking statements contained in this

Document. Each of the Company and its affiliates controlling persons directors officers partners employees agents representatives or advisers of any of the foregoing assumes no obligation to update or otherwise

revise these forward-looking statements for new information events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates controlling persons directors officers partners

employees agents representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of or reliance upon the information contained herein by you or any person

to whom the information herein is disclosed.In furnishing this Document the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may

become apparent.

2C o n t e n t s

Performance Segment Financial Future

Overview Highlights Highlights Outlook

31234

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

42024 Highlights

Solid Revenue Growth Global Platform & Customers Rich Pipeline to Fuel Future Growth

RMB12276 mm in revenue YoY growth of 900+ new customers 3000+ active Discovery projects: 781 drug discovery

6.4%. With 2H24 revenue at RMB6671 projects

customers including all of the TOP 20

mm YoY growth of 13.1%

global pharmas CMC projects: 19 in validation &

RMB1793 mm in net profit YoY growth of commercial 23 in PhIII 242 in PhI/II 782

12.0% 21 R&D & manufacturing facilities across in preclinical

RMB1607 mm in non-IFRSs adjusted net China UK & US providing fully-

Clinical projects: 1062 CRO projects

profit YoY decline of 15.6% integrated services for SM LM & CGT including 94 in PhIII. 1600+ SMO projects

New POs increased by 20%+ YoY CRC team covers 670+ hospitals &

21370 employees including 1700+

clinical trial centers in 150+ cities

Financial performances improved QoQ overseas employees. 19192 scientists &

and YoY revenue growth rate accelerated CGT projects: 24 release testing projects

each quarter as a result of the initial technicians representing ~90% of total including 2 commercial projects. 14 gene

recovery of the global biotech funding employees therapy CDMO projects including 1 in

environment. The Company continued to

PhIII 6 in PhI/II 7 in preclinical

gain market share globally

Data are rounded to the nearest million 52024 Performances Improved QoQ & YoY Revenue Growth Rate Accelerated Each Quarter

Continuous Improvement of Net Margin in 3Q&4Q RMB mm 1Q2024 2Q2024 3Q2024 4Q2024

Revenue Non-IFRSs Net Profit Non-IFRSs Net Margin Revenue 2671 2934 3213 3458

RMB mm 3458

3500.0015%

3213

2934 14.4% QoQ 9.8% 9.5% 7.6%

3000.00

267114%

2500.00

YoY -2.0% 0.6% 10.0% 16.1%

13.0%13%

2000.00

12.7%

1500.00

12.0% 12% Non-IFRSs Net Profit 339 351 417 499

1000.00

49911%

500 .00 339 351 417 QoQ 3.7% 18.7% 19.7%

-10%

1Q2024 2Q2024 3Q2024 4Q2024 YoY -22.7% -28.8% -13.2% 1.7%

Data are rounded to the nearest million 62024 Revenue Compositions

Segments Revenue Composition Global Customers Revenue Composition

Biologics & CGT ROW 2%

Services 3% NA Revenue Grew 6.1%

Clinical Development China

Services 15% EU Revenue Grew 23.2% 15%

Laboratory CN Revenue Declined 6.5% North

Services 57% Europe America

19%64%

Small Molecule

CDMO Services

24%

China/Overseas Entities Revenue Composition Diversified Customer Base Revenue Composition

New Customers

5%

China Entities Overseas TOP 20 Pharmas TOP 20

Subsidiaries

Revenue Grew 7.8% Revenue Grew 26.9% Pharmas

13%18%

Overseas Subsidiaries Other Customers

Revenue Declined 2.7% Revenue Grew 2.8%

China Entities Other Repeat

87% Customers 77%

7ESG Updates

ESG Ratings SBTi Sustainable Development

* Included in S&P Global

Sustainability Yearbook 2025

2024 MSCI ESG Rating * Pharmaron’s SBT have been

validated by SBTi in June 2024 * Included in S&P China

AA

* Total GHG emissions declining by Sustainability Yearbook 2025

20%+ in 2024

SUSTAINALYTICS 2025

2024 CDP 2024 EcoVadis

* Regional TOP Rated ESG Company Climate Change Bronze Prize

* Industry TOP Rated ESG Company Questionnaire: B

81234

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

9Laboratory Services

RMB mm 1Q2024 2Q2024 3Q2024 4Q2024 2024

Revenue 1605 1767 1847 1828 7047

QoQ 10.1% 4.6% -1.0%

YoY -2.9% 2.3% 9.4% 14.9% 5.8%

GPM 43.6% 44.3% 44.9% 44.7% 44.4%

QoQ 0.7pct 0.6pct -0.2%

YoY -0.7pct -1.0pct 2.1pct 1.2pct 0.4pct

? Robust YoY revenue growth of bioscience services which accounted for 54%+ of the

segment’s total revenue; Laboratory chemistry services achieved the highest quarterly

revenue record of the year in 4Q2024

? New POs increased by 15%+ YoY

? Participated in 781 drug discovery projects

? Leveraging comprehensive & multi-dimensional data to assist our customers: (1) Maintained

focus on cutting-edge technologies and emerging therapeutic targets; (2) Expanded and

upgraded HTS and automation platforms; (3) Strengthened capabilities in 3D cell culture

organoids animal models and omics analysis; (4) Strengthened capabilities for new

modalities; (5) Explored the application of AI and machine learning in laboratory services

Data are rounded to the nearest million 10CMC (Small Molecule CDMO) Services

RMB mm 1Q2024 2Q2024 3Q2024 4Q2024 2024

Revenue 582 594 801 1012 2989

QoQ 2.0% 34.9% 26.4%

YoY -2.7% -9.1% 20.9% 26.9% 10.2%

GPM 27.3% 28.3% 34.1% 38.4% 33.1%

QoQ 1.0pct 5.8pct 4.3pct

YoY -5.4pct -3.4pct 2.0pct 2.2pct -0.3pct

? ~81% of CMC services revenue came from the existing customers of laboratory services

? New POs increased by 35%+ YoY. More large-scale production projects

? Commercial manufacturing: DP commercial manufacturing of 2 newly approved innovative

drugs in China; Ningbo API facility received FDA PAI and is awaiting the final EIR

? Invested in new technologies to improve productivity: end-to-end continuous flow synthesis

continuous hydrogenation reactions continuous flow ozonolysis biocatalysis electrochemistry

photochemistry HTE and high potency API manufacturing

? Increased costs due to certain modules in Shaoxing facility transferred from CIP into fixed

assets in 4Q2023 and increased labor costs. Improved GMP in 2H2024 as a result of

increased revenue

Data are rounded to the nearest million 11Innovative Drug CMC Projects Continued to Advance to Late Stage

Total +181

+123

782 Preclinical

+72

242 Phase I/II

-4

23 Phase III

Innovative Drugs +4

19 PPQ&Commercial

12Clinical Development Services

RMB mm 1Q2024 2Q2024 3Q2024 4Q2024 2024

Revenue 392 452 463 520 1826

QoQ 15.4% 2.4% 12.4%

YoY 4.6% 4.8% 1.3% 9.5% 5.1%

GPM 9.3% 15.4% 14.4% 11.9% 12.8%

QoQ 6.1pct -1.0pct -2.5pct

YoY -4.7pct -4.2pct -6.1pct -2.0pct -4.3pct

? As a result of synergies of the Company’s integrated platform and increasing customer

recognitions of Pharmaron Clinical the Company has continued to increase its number of

projects and gain market share

? 1062 clinical CRO projects including 94 PhIII clinical trials 407 PhI/II clinical trials and 561

other clinical trials. 1600+ SMO projects. CRC team covers 670+ hospitals & clinical trial

centers in 150+ cities

? Tested evaluated and implemented multiple AI applications across various business units.Acquired controlling stake in Aistarfish to accelerate the digital and AI transformation of clinical

development services

? GPM declined due to revenue mix of different projects and competitions in China market

Data are rounded to the nearest million 13Biologics & CGT Services

RMB mm 1Q2024 2Q2024 3Q2024 4Q2024 2024

Revenue 91 120 100 97 408

QoQ 31.0% -16.7% -3.2%

YoY -4.1% 14.3% -9.6% -15.5% -4.1%

GPM -38.6% -25.9% -67.2% -73.5% -50.1%

QoQ 12.7pct -41.3pct -6.3pct

YoY -26.8pct -20.6pct -61.8pct -62.4pct -41.8pct

? Biologics CDMO: successfully completed the 1st integrated project from DNA to DS/DP for an

innovative bispecific antibody

? CGT testing: 24 CGT analytical release testing projects including 2 commercial projects and 9

clinical projects. 22 GLP & non-GLP toxicology studies for CGT products either had been

completed or are in progress

? GT CDMO: 14 gene therapy CDMO projects including 1 in PhIII 6 in PhI/II & 7 in preclinical

? The emerging segment is still in the investment stage. Increased operating costs and

depreciation of the biologics CDMO capacity in Ningbo

Data are rounded to the nearest million 141 2 3 4

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

152024 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1)

13.4%12.7%12.8%

2.1%2.2%2.2%2.1%11.3%

20212022202320242021202220232024

R&D Costs as % of Total Revenue Net Finance Costs as % of Total Revenue (2)

3.9%3.8%

0.9%

2.9%

0.1%0.1%

2.0%

2021202220232024

(1.2)%

2021202220232024

1. Excluding share-based compensation expenses recognized in administrative expenses 16

2. Net finance costs including interest expenses on bank borrowings and lease liabilities interest income and bank wealth management products related gains or lossesFree Cash Flow of RMB536 Million in 2024

RMB mm

29502865

2754

2577

2058209321432041

2021202220232024

Net Operating Cash Flow CAPEX

Data are rounded to the nearest million 172024 Non-IFRSs Adjusted Net Profit

RMB mm 2024 2023

Net Profit 1793 1601

Add:

Share-based Compensation Expenses 83 185

Convertible Bonds Related (Gains) / Losses (6) 123

Foreign Exchange Related Losses / (Gains) 34 (6)

Realized and Unrealized (Gains) / Losses From Equity

(407)0

Investments

Non-Financial Assets Impairment 65 -

One-off Loss Made by Pharmaron Shanghai Co. Ltd.

44-

due to the Business Close

Non-IFRSs Net Profit 1607 1903

Data are rounded to the nearest million 181 2 3 4

CONTENT Performance Segment Financial Future

Overview Highlights Highlights Outlook

192025 Outlook

The industry fundamentals remain intact. Customer demand & POs showing recovery signs

2024 performances improved QoQ and YoY revenue growth rate accelerated each quarter

Continue to develop our end-to-end fully integrated and multiple modalities-capable

services platform with global footprints to further support our customers in improving

the efficiency and flexibility of their pharmaceutical R&D and manufacturing needs

Expect to deliver 10~15% revenue growth in 2025

Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about

the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties and accordingly actual results may differ 20

materially from these forward-looking statementsTHANK YOU